CAR T-cell therapy Carvykti shows promise in early myeloma
A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who…
A single infusion of the CAR T-cell therapy Carvykti (ciltacabtagene autoleucel) was sufficient to control disease activity in most multiple myeloma patients who…
Arcellx and Kite Pharma are planning to launch a Phase 3 clinical trial, dubbed iMMagine-3, to test their cell therapy anitocabtagene…
At its 15th annual gala, held in New York City this April, the International Myeloma Foundation (IMF) raised more than $675,000 — monies the…
A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…
Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be…
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…